Clinical trial
Effect of Repaglinide Versus Metformin Treatment in Combination With Insulin Biasp30 (Novologmix 70/30) Predinner on Glycemic and Non-Glycemic Cardiovascular Risk-Factors in Non-Obese Patients With Type-2-Diabetes With Unsatisfactory Glycaemic Control With Oral Hypoglycaemic Agents
NCT00118963 is registered in ClinicalTrials.gov with Steno Diabetes Center Copenhagen as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Effect of Repaglinide Versus Metformin Treatment in Combination With Insulin Biasp30 (Novologmix 70/30) Predinner on Glycemic and Non-Glycemic Cardiovascular Risk-Factors in Non-Obese Patients With Type-2-Diabetes With Unsatisfactory Glycaemic Control With Oral Hypoglycaemic Agents
- Lead sponsor
- Steno Diabetes Center Copenhagen
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- January 31, 2003
- Completion date
- February 28, 2006
- Enrollment
- 102 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.